Skip to main content

Drug Interactions between axitinib and faricimab ophthalmic

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

axitinib faricimab ophthalmic

Applies to: axitinib and faricimab ophthalmic

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration of ophthalmic faricimab with other anti-vascular endothelial growth factor (VEGF) and/or other therapies (e.g., photodynamic therapy) for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema (DMO), and/or visual impairment due to macular edema secondary to retinal vein occlusion (RVO) in the same eye has not been evaluated.

MANAGEMENT: According to some authorities, concomitant use of ophthalmic faricimab with other anti-VEGF products, systemic or ocular, and/or other therapies (e.g., photodynamic therapies) in the same eye should generally be avoided. Clinical data characterizing the extent of this interaction are not available. Consultation with package labeling and relevant institutional protocols may be advisable for further guidance.

Drug and food/lifestyle interactions

Moderate

axitinib food/lifestyle

Applies to: axitinib

Do not consume grapefruit or grapefruit juice during treatment with axitinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of axitinib. This may increase the risk and/or severity of side effects such as high blood pressure, diarrhea, nausea, vomiting, constipation, decreased appetite, weight loss, and rash, itching or peeling of skin on the hands and feet. You may also be more likely to experience less common but more severe side effects such as blood clots (depending on location, can lead to complications such as stroke, heart attack, breathing difficulties, and vision abnormalities); bleeding; liver problems; thyroid problems; tearing (perforation) in the stomach or intestinal wall; and a rare nervous system condition known as reversible posterior leukoencephalopathy syndrome (RPLS). You should seek immediate medical attention if you develop signs and symptoms of these conditions including chest pain or pressure; pain in the arms, back, neck or jaw; swelling; shortness of breath; numbness or weakness on one side of the body; headache; vision changes; seizures, unusual bleeding or bruising; red or black stools; coughing up or vomiting blood or blood clots; and severe stomach or abdominal pain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.